Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation
about
Safe handling of oral antineoplastic medications: focus on targeted therapeutics in the home settingCytotoxic and targeted therapy for hereditary cancersTargeting DNA Replication Stress for Cancer TherapyOvarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease PreventionNew treatment option for ovarian cancer: PARP inhibitorsTrial watch - inhibiting PARP enzymes for anticancer therapyProfile of olaparib in the treatment of advanced ovarian cancerTargeted agents in epithelial ovarian cancer: review on emerging therapies and future developmentsRole of Biomarkers in the Development of PARP InhibitorsDNA repair targeted therapy: The past or future of cancer treatment?DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of CancerEmerging mechanisms of resistance to androgen receptor inhibitors in prostate cancerMET deregulation in breast cancerTriple negative breast cancer: looking for the missing link between biology and treatmentsOlaparib in the management of ovarian cancerPerspectives in the treatment of pancreatic adenocarcinomaPARP inhibitors in the management of breast cancer: current data and future prospectsPancreatic cancer: optimizing treatment options, new, and emerging targeted therapiesProfile of veliparib and its potential in the treatment of solid tumorsPARP inhibitors and moreA phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - AnIntegrative clinical genomics of advanced prostate cancer.DNA-Repair Defects and Olaparib in Metastatic Prostate CancerPerspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancerMolecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and TreatmentPancreatic cancer: New hopes after first line treatmentPARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directionsPredictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized MedicineRecent developments and translational aspects in targeted therapy for metastatic breast cancerChemoresistance and targeted therapies in ovarian and endometrial cancersIs it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?Genetic factors affecting patient responses to pancreatic cancer treatmentUpdate on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatmentConcepts and targets in triple-negative breast cancer: recent results and clinical implicationsImplementing Genome-Driven Oncology.DNA-damaging autoantibodies and cancer: the lupus butterfly theory.A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumoursSynthetic lethality: emerging targets and opportunities in melanoma.Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies.PARP inhibitors in ovarian cancer: evidence, experience and clinical potential
P2860
Q23923997-E3114427-B96B-4E72-99F2-E5CFA90AF3A3Q26739366-962D5981-FDB0-4673-945B-1051B9D9FD82Q26739923-DB38689D-33D5-4555-B8D4-266028739C72Q26744525-2ED93225-AA16-4D62-AB6F-C2DFC33DF24FQ26745614-DA8FD72E-D374-4AAD-9AEE-4C91094D2774Q26745673-22068C42-9A6B-4810-A46D-2AF6CF422131Q26749284-DD631999-1A28-40A6-AB0D-BF403E000D7FQ26750649-BEA70434-45F5-42C9-A908-C40DF4766304Q26753159-CA479F22-1DB7-4AE9-BB65-E72B661FAEE0Q26768679-38A918F7-C3A0-462D-8ED2-3F8575525349Q26776513-4BA9DCF3-C26E-485C-8D6F-D14DC0D115E3Q26777310-49018444-A980-4568-9289-37E3EC56F250Q26781054-F6115255-61D2-44E5-A24B-9B352C7D1AC3Q26783122-17C1A2E7-9EB1-4C2F-8880-A28215B0B78AQ26797166-FAB4F8D6-B1BF-4C6B-B321-9A803489F8F7Q26797248-9607C983-EEF6-4308-8BF6-66FF037C1CE7Q26798352-113F354F-E46A-47D8-913C-A4DA9E42E27AQ26799714-9CCC36C8-3169-45CE-9DC5-03095F162E20Q26801272-20A28805-AED4-4726-B1F1-599734E77947Q27027014-787D0150-B404-4FD6-B782-4F5DE255029AQ27302763-6A4ECD22-0653-4FB7-9907-24CB7B7918CAQ27853170-1C325B9C-1FFE-478F-9F0A-9A3F719CDD44Q27853235-9C9ADE92-13BF-474B-B487-E7454DC373DCQ28066320-BBDD7101-013F-409F-A3B4-5158B5BF91FCQ28066904-9364CC01-50BE-4530-9A05-0274232FC5DBQ28067055-2B956943-4E55-4104-8BCA-D73BCCFFE812Q28071345-78924CF3-950F-4D3A-95AD-7EDAFADD5A23Q28072204-3BA32C92-0074-4740-8D35-1541507B526EQ28072755-C4000054-6002-496D-9A36-D58F37D3CC79Q28073246-D0E41E93-3477-4A8D-A7C8-61A9CD62C499Q28073673-2A819D41-6340-469F-A553-1733E8181D67Q28075293-D24D5C9C-1F33-4CD2-9CA7-73AA4B1E638DQ28075761-D41C1282-7F5B-4D81-8767-7BD431D447AEQ28078992-FD286BB4-FA91-4743-82EC-2D1EF2D4AD27Q30235979-17804950-FAA5-4303-8ECF-69AE4FDA258DQ30251723-090E00C1-E12E-4295-B9D6-388280A71A85Q33439527-4BE11EA3-CC0F-4227-8171-98C1E95D0DE7Q33578398-C0FD4213-3695-45BD-8338-1CA4FA1360BBQ33591876-88EC720C-BA2E-484D-90D5-25E632717251Q33605912-5C750880-4780-46E3-A1B5-ADB7F22F3EF1
P2860
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation
description
im November 2014 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 03 November 2014
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в листопаді 2014
@uk
name
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation
@en
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation
@nl
type
label
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation
@en
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation
@nl
prefLabel
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation
@en
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation
@nl
P2093
P2860
P50
P356
P1476
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation
@en
P2093
Anitra Fielding
Ayala Hubert
Bella Kaufman
Georgeta Fried
Gillian Mitchell
Karin Bowen
M William Audeh
Mariana Steiner
Michael Friedlander
Niklas Loman
P2860
P304
P356
10.1200/JCO.2014.56.2728
P407
P577
2014-11-03T00:00:00Z